TAK 906

Drug Profile

TAK 906

Alternative Names: TAK 906 Maleate; TAK906

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda Oncology
  • Class
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastroparesis

Most Recent Events

  • 24 Nov 2017 Phase-II clinical trials in Gastroparesis in USA (PO) (3285061; Takeda Q2 report,
  • 07 Oct 2017 Takeda completes a phase I trial in Gastroparesis (In volunteers) in Japan (PO) (NCT03237156) (JapicCTI-173661)
  • 04 Sep 2017 Millennium Pharmaceuticals plans a phase II trial for Diabetes mellitus and Gastroparesis (NCT03268941)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top